- Home
- XGN
XGN
Exagen Inc.
as 11-15-2024 4:00pm EST
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | VISTA |
| Market Cap: | 44.7M | IPO Year: | 2019 |
| Target Price: | $7.00 | AVG Volume (30 days): | 21.5K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $3.71 | Next Earning Date: | 11-12-2024 |
| Revenue: | $55,751,000 | Revenue Growth: | 8.00% |
| Revenue Growth (this year): | 9.98% | Revenue Growth (next year): | 13.63% |
Latest Exagen Inc. News
XGN Breaking Stock News: Dive into XGN Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Exagen Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
GlobeNewswire
3 days ago
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
GlobeNewswire
4 days ago
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
GuruFocus.com
5 days ago
Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ...
Thomson Reuters StreetEvents
5 days ago
Q3 2024 Exagen Inc Earnings Call
Zacks
5 days ago
Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates
Simply Wall St.
6 days ago
November 2024 Penny Stocks On US Exchanges To Consider
GuruFocus.com
6 days ago
Exagen Inc (XGN) Q3 2024 Earnings Report Preview: What To Expect
Compare XGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XGN Exagen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.